Highlights
Revenue
from continuing operations
+12.7%
to R26.9 billion
Normalised EBITDA* from continuing operations of +21.6 % to R5.1 billion
Cash generated from
operations of R5.7 billion
Normalised earnings per share (NEPS)*
from continuing operations
+88.3%
to 109.8 cents
Completed disposal of Scanmed for a total cash consideration of R733 million
Strong financial position with
available undrawn facilities of
R6.6 billion
* Non-IFRS measures.